Overview of the diagnosis and treatment of stuttering

Journal of Experimental and Clinical Medicine

Volumn 4, Issue 2, 2012, Pages 92-97

  Maguire, Gerald A ^a   Yeh, Christopher Y ^a   Ito, Brandon S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dopamine hypothesis of stuttering; Medication; Stuttering

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; BENZODIAZEPINE; HALOPERIDOL; OLANZAPINE; PAGOCLONE; PLACEBO; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VERAPAMIL;

AMENORRHEA; ANXIETY; COGNITION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG TOLERABILITY; DYSPHORIA; EXTRAPYRAMIDAL SYMPTOM; FLUENCY DISORDER; GALACTORRHEA; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HEREDITY; HUMAN; HYPERPROLACTINEMIA; IMAGE ANALYSIS; MEDICAL PRACTICE; PATIENT COMPLIANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; STUTTERING; WEIGHT GAIN;

EID: 84859570928     PISSN: 18783317     EISSN: 18783325     Source Type: Journal    
DOI: 10.1016/j.jecm.2012.02.001     Document Type: Review

References (64)

1. Andrews G., Craig A., Feyer A., Hoddinott S., Howie P., Neilson M. Stuttering: a review of research findings and theories circa 1982. J Speech Hear Disord 1983, 48:226-263.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 4th Ed., Text Revision. (DSM-IV-TR) 2000, American Psychiatric Association, Washington, DC.
3. Guitar B.E. Stuttering and stammering. Pediatr Rev 1985, 7:163-168.
4. Maguire G. Without hesitation: speaking to the silence and the science of stuttering 2010, National Stuttering Association, New York, NY.
5. Mansson H. Childhood stuttering: incidence and development. J Fluency Disord 2000, 25:47-57.
6. Bloodstein O. A handbook on stuttering 1995, Singular Publishing Group, San Diego, CA. 5th ed.
7. Yairi E., Ambrose N.G. Early childhood stuttering: I. Persistency and recovery rates. J Speech Lang Hear Res 1999, 42:1097-1112.
8. Ludlow C.L., Dooman A.G. Genetic aspects of idiopathic speech and language disorders. Otolaryngol Clin North Am 1992, 25:979-994.
9. Riley G., Ingham J. Acoustic duration changes associated with two types of treatment for children who stutter. J Speech Hear Disord 2000, 43:965-978.
10. DSM-5: Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (Proposed Revision): Childhood Onset Fluency Disorder December 9, 2010, American Psychiatric Association, Available from:, Retrieved December 20, 2011. http://www.dsm5.org.
11. Orton S.T. Studies in stuttering. Arch Neurol Psychiatry 1927, 18:671-672.
12. Travis L.E. Speech pathology 1931, Appleton-Century-Crofts, New York.
13. Andrews G., Craig A. Prediction of outcome after treatment for stuttering. Br J Psychiatry 1988, 153:236-240.
14. Howie P.M. Concordance for stuttering in monozygotic and dizygotic twin pairs. J Speech Hear Res 1981, 24:317-321.
15. Maguire G., Franklin D., Vatakis N.G., Morgenshtern E., Denko T., Yaruss J.S., Spotts C., et al. Exploratory randomized clinical study of pagoclone in persistent developmental stuttering: the examining Pagoclone for persistent developmental stuttering study. J Clin Psychopharmacol 2010, 30:48-56.
16. Iverach L., Jones M., O'Brian S., Block S., Lincoln M., Harrison E., Hewat S., et al. Mood and substance use disorders among adults seeking speech treatment for stuttering. J Speech Lang Hear Res 2010, 53:1178-1190.
17. Iverach L., O'Brian S., Jones M., Block S., Lincoln M., Harrison E., Hewat S., et al. Prevalence of anxiety disorders among adults seeking speech therapy for stuttering. J Anxiety Disord 2009, 23:928-934.
18. Blumgart E., Tran Y., Craig A. Social anxiety disorder in adults who stutter. Depress Anxiety 2010, 27:687-692.
19. Lan J., Song M., Pan C., Zhuang G., Wang Y., Ma W., Chu Q., et al. Association between dopaminergic genes (SLC6A3 and DRD2) and stuttering among Han Chinese. J Hum Genet 2009, 54:457-460.
20. Petrin A.L., Giacheti C.M., Maximino L.P., Abramides D.V., Zanchetta S., Rossi N.F., Richieri-Costa A., et al. Identification of a microdeletion at the 7q33-q35 disrupting the CNTNAP2 gene in a Brazilian stuttering case. Am J Med Genet A 2010, 152A:3164-3172.
21. Drayna D., Kang C. Genetic approaches to understanding the causes of stuttering. J Neurodev Disord 2011, 3:374-380.
22. Maguire G.A., Viele S.N., Agarwal S., Handler E., Franklin D. Stuttering onset associated with streptococcal infection: a case suggesting stuttering as PANDAS. Ann Clin Psychiatry 2010, 22:283-284.
23. Alm P.A. Stuttering and the basal ganglia circuits: a critical review of possible relations. J Commun Disord 2004, 37:325-369.
24. Church A.J., Dale R.C., Lees A.J., Giovannoni G., Robertson M.M. Tourette's syndrome: a cross sectional study to examine the PANDAS hypothesis. J Neurol Neurosurg Psychiatry 2003, 74:602-607.
25. Maguire G.A., Riley G.D., Yu B.P. A neurological basis of stuttering. Lancet Neurol 2002, 1:407.
26. Kurlan R., Kaplan E.L. The pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) etiology for tics and obsessive-compulsive symptoms: hypothesis or entity? practical considerations for the clinician. Pediatrics 2004, 113:883-886.
27. Watkins K.E., Smith S.M., Davis S., Howell P. Structural and functional abnormalities of the motor system in developmental stuttering. Brain 2008, 131:50-59.
28. Wu J.C., Maguire G.A., Riley G., Fallon J., LaCasse L., Chin S., Klein E., et al. A positron emission tomography [18F] deoxyglucose study of developmental stuttering. Neuroreport 1995, 6:501-505.
29. Wu J.C., Maguire G., Riley G., Lee A., Keator D., Tang C. Increased dopamine activity associated with stuttering. Neuroreport 1997, 8:767-770.
30. Sommer M., Koch M.A., Paulus W., Weiller C., Buchel C. Disconnection of speech-relevant brain areas in persistent developmental stuttering. Lancet 2002, 360:380-383.
31. Salmelin R., Schnitzler A., Schmitz F., Freund H.J. Single word reading in developmental stutterers and fluent speakers. Brain 2000, 123:1184-1202.
32. Brown S., Ingham R.J., Ingham J.C., Laird A.R., Fox P.T. Stuttered and fluent speech production: an ALE meta-analysis of functional neuroimaging studies. Hum Brain Mapp 2005, 25:105-117.
33. Lu C., Chen C., Ning N., Ding G., Guo T., Peng D., Yang Y., et al. The neural substrates for atypical planning and execution of word production in stuttering. Exp Neurol 2010, 221:146-156.
34. Neef N.E., Paulus W., Neef A., von Gudenberg A.W., Sommer M. Reduced intracortical inhibition and facilitation in the primary motor tongue representation of adults who stutter. Clin Neurophysiol 2011, 122:1802-1811.
35. Burd L., Kerbeshian J. Stuttering and stimulants [letter]. J Clin Psychopharmacol 1991, 11:72-73.
36. Anderson J.M., Hughes J.D., Rothi L.J., Crucian G.P., Heilman K.M. Developmental stuttering and Parkinson's disease: the effects of levodopa treatment. Neurol Neurosurg Psychiatry 1999, 66:776-778.
37. Rosenberger P.B., Wheelden J.A., Kalotkin M. The effect of haloperidol on stuttering. Am J Psychiatry 1976 Mar, 133(3):331-334.
38. Rothenberger A., Johannsen H.S., Schulze H., Amorosa H., Rommel D. Use of tiapride on stuttering in children and adolescents. Percept Mot Skills 1994, 79:1163-1170.
39. Maguire G.A., Riley G.D., Franklin D.L., Gottshalk L.A. Risperidone for the treatment of stuttering. J Clin. Psychopharmacol 2000, 20:479-482.
40. Maguire G., Riley G., Franklin D., Maguire M., Nguyen C., Brojeni P. Olanzapine in the treatment of developmental stuttering: a double-blind, placebo-controlled trial. Ann Clin Psychiatry 2004, 16:63-67.
41. Mulligan H.F., Anderson T.J., Jones R.D., Williams M.J., Donaldson I.M. Tics and developmental stuttering. Parkinsonism Relat Disord 2003, 9:281-289.
42. Tran N.L., Maguire G.A., Franklin D.L., Riley G.D. Case report of aripiprazole for persistent developmental stuttering. J Clin Pharmacol 2008, 28:470-472.
43. Yoo H.K., Choi S.H., Park S., Wang H.R., Hong J.P., Kim C.Y. An open-label study of efficacy and tolerability of aripiprazole for children and adolescents with tic disorders. J Clin Psychiatry 2007, 68:1088-1093.
44. Giraud A.L., Neumann K., Bachoud-Levi A.C., von Gudenberg A.W., Euler H.A., Lanfermann H., Preibisch C. Severity of dysfluency correlates with basal ganglia activity in persistent developmental stuttering. Brain Lang 2008, 104:190-199.
45. Blomgren M., Roy N., Callister T., Merrill R.M. Intensive stuttering modification therapy: a multidimensional assessment of treatment outcomes. J Speech Lang Hear Res 2005, 48:509-523.
46. Brady J.P. The pharmacology of stuttering: a critical review. Am J Psychiatry 1991, 148:1309-1316.
47. Buchsbaum M.S., Potkin S.G., Siegel B.V., Lohr J., Katz M., Gottschalk L.A., Gulasekaram B., et al. Striatal metabolic rate in clinical response to neuroleptics in schizophrenia. Arch Gen Psychiatry 1992, 49:966-974.
48. Brady J.P., Mcallister T.W., Price T.R. Verapamil in stuttering [letter]. Biol Psychiatry 1990, 27:680-681.
49. Maguire G., Riley G., Hahn R., Plon L. Nimodipine in the treatment of stuttering. ASHA J 1994, 36:51.
50. Stager S., Calis K., Grothe D., Bloch M., Turcasso N., Ludlow C., Braun A. A double-blind trial of pimozide and paroxetine for stuttering. Speech production: Motor control, brain research and fluency disorders 1997, 379-382.
51. Yannatos G. L'hydroxyzine dans la therapeutique des bégaiements. J Fr Otorhinolaryngol Chir Maxillofac 1960, 9:293-296. [in French].
52. Murray T.J., Kelly P., Campbell L., Stefanik K. Haloperidol in the treatment of stuttering. Br J Psychiatry 1977, 130:370-373.
53. Maguire GA. The dopamine hypothesis of stuttering and its treatment implications. Presented at Collegium Internationale Neuro-Psychopharmacologicum. Brussels, Belgium. July 2000.
54. Margolese HC, Annabel L, Dion Y. Depression and dysphoria in adult and adolescent patients with Tourette syndrome treated with risperidone. Presented at the American College of Neuropsychopharmacology, Waikoloa, HI, USA December 10, 2001.
55. Tavano A., Busan P., Borelli M., Pelamatti G. Risperidone reduces tic-like motor behaviors and linguistic dysfluencies in severe persistent developmental stuttering. J Clin Psychopharmacol 2011, 31:131-134.
56. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Anderson S.W., Beasley C., Tollefson G.D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997, 17:407-441.
57. Lavid N., Franklin D.L., Maguire G.A. Management of child and adolescent stuttering with olanzapine: three case reports. Ann Clin Psychiatry 1999, 11:233-236.
58. Catalano G., Robben D.L., Catalano M.C., Kahn D.A. Olanzapine for the treatment of acquired neurogenic stuttering. J Psychiatr Pract 2009, 15:484-488.
59. Schoemaker J., Naber D., Vrijland P., Panagides J., Emsley R. Long-term assessment of asenapine vs olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry 2010, 43:138-146.
60. Maguire G.A., Franklin D.L., Kirsten J. Asenapine for the treatment of stuttering: an analysis of three cases. Am J Psychiatry 2011, 168:651-652.
61. Maguire G, Yaruss S. NSA Convention. Anaheim, CA. June 2002.
62. Boberg E., Kully D. Long-term results of an intensive treatment program for adults and adolescents who stutter. J Speech Hear Res 1994, 37:1050-1059.
63. Manning W.H. Clinical decision-making in fluency disorders 2001, Singular, Calgary, Canada. 2nd ed.
64. Maguire G.A., Yu B.P., Franklin D.L., Riley G.D. Alleviating stuttering with pharmacological interventions. Expert Opin Pharmacother 2004, 5:1565-1571.